Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-613 for Prophylaxis of Acute Gout Flares
NCT06270225Phase 2Active, not recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-613 in gouty arthritis, sponsored by 3S Guojian Pharmaceutical. Started Mar 2024; status: active, not recruiting.
02
Drugs
SSGJ-613
03
Conditions
gouty arthritis
Beyond the preview
Go deeper on NCT06270225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270225.